Form 4: PMV Pharmaceuticals Director Granted 33,500 Stock Options

Carol Giltner Gallagher, a Director at PMV Pharmaceuticals, Inc., has been granted 33,500 stock options with an exercise price of $0.95, vesting by June 2026 or the next annual meeting.

Summary

• Carol Giltner Gallagher, a Director of PMV Pharmaceuticals, Inc. (PMVP), was granted 33,500 stock options on June 5, 2025.
• The exercise price for these stock options is $0.95 per share.
• The options are set to vest on the earlier of June 5, 2026, or the date of the Issuer's next annual meeting of stockholders.
• These options have an expiration date of June 5, 2035.
• The 33,500 stock options are beneficially owned indirectly through The Gallagher Revocable Trust dated May 10, 2011, for which Ms. Gallagher serves as a trustee.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options to a director is a standard practice that aligns management's interests with shareholders, indicating a commitment to long-term value creation. It is not highly impactful on its own but contributes to good corporate governance.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance of the company's stock.
• The exercise price of $0.95 provides a clear incentive for the director to contribute to the company's share price appreciation.

Negatives

• No specific negatives are indicated in this Form 4 filing, as it primarily reports a standard compensation event.

Future Outlook

The document indicates future vesting of stock options by June 5, 2026, or the date of the next annual meeting of stockholders, and an option expiration date of June 5, 2035, reflecting a long-term incentive structure.

Industry Context

This Form 4 filing represents a routine insider transaction, specifically the grant of equity compensation to a director, which is a common practice across industries, particularly in biotechnology and pharmaceutical sectors like PMV Pharmaceuticals, to incentivize leadership and align their interests with shareholder value.

Comparison to Industry Standards

• The grant of stock options to a director is a standard form of executive and board compensation across publicly traded companies, including those in the biotechnology sector.
• The vesting schedule, tied to a specific date or the next annual meeting, is a common mechanism to ensure continued service and performance alignment.
• The exercise price being set at a specific value ($0.95) is typical for compensatory option grants, often reflecting the stock price at the time of grant or a predetermined value.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will vest on the earlier of June 5, 2026, or the date of the Issuer's next annual meeting of stockholders.
• The director may exercise the vested options at any time before the expiration date of June 5, 2035.

Key Dates

Keywords

PMV Pharmaceuticals, PMVP, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Corporate Governance